Strategies and Applications of Antigen-Binding Fragment (Fab) Production in Escherichia coli

Authors:

Abstract
With the advancement of genetic engineering, monoclonal antibodies (mAbs) have made far-reaching progress in the treatment of various human diseases. However, due to the high cost of production, the increasing demands for antibody-based therapies have not been fully met. Currently, mAb-derived alternatives, such as antigen-binding fragments (Fab), single-chain variable fragments, bispecifics, nanobodies, and conjugated mAbs have emerged as promising new therapeutic modalities. They can be readily prepared in bacterial systems with well-established fermentation technology and ease of manipulation, leading to the reduction of overall cost. This review aims to shed light on the strategies to improve the expression, purification, and yield of Fab fragments in Escherichia coli expression systems, as well as current advances in the applications of Fab fragments. # These authors contributed equally to this work. Received: 27 May 2021 Accepted: 03 July 2021 Article published online: 02 September 2021 © 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/) Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany
Funding Information
  • National Natural Science Foundation of China (2070722)
  • National Science and Technology Major Project (2019ZX09201001-003-008)
  • Shanghai Jiao Tong University Medicine Engineering Joint Funding (YG2019ZDA04)
  • Shanghai Jiao Tong University Medicine Engineering Joint Funding (YG2019QNA50)

This publication has 86 references indexed in Scilit: